Guía detallada disponible en inglés. MFMD ofrece orientación y coordinación del centro en español.
A new hormone therapy should enter the practice through a defined service-line review — not because a vendor introduced a new product or patients started asking for it. Review the clinical purpose, prescriber, product, pharmacy, controlled-substance status, staffing, documentation, and monitoring model before it reaches the menu.
Abrir la explicación completa2 secciones y fuentes primarias
What belongs on the review checklist before adding a hormone therapy?
What exact hormone/product is proposed and its intended use? Is it commercially available or compounded? Is it controlled? Who prescribes, and who administers or performs the procedure? What pharmacy/source is used? What patient evaluation is required, and what documentation and monitoring/escalation change? Does it need new supplies/equipment, or affect insurance, malpractice, or AHCA structure?
Owner takeaway
Treat a new hormone product as a clinical service-line decision, not a menu update. See Add a Service Line to structure it.